NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Ascending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
62856-0796-01 | 62856-0796 | Netupitant and Palonosetron | Akynzeo | 300.0 mg/1, 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Oral | Oct. 13, 2014 | May 31, 2018 | No Longer Used |
62856-0796-04 | 62856-0796 | Netupitant and Palonosetron | Akynzeo | 300.0 mg/1, 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Oral | Oct. 13, 2014 | Oct. 13, 2014 | No Longer Used |
62856-0798-01 | 62856-0798 | Palonosetron hydrochloride | Aloxi | 0.075 mg/1.5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 28, 2014 | June 30, 2018 | In Use |
67296-1738-07 | 67296-1738 | Metoclopramide | Metoclopramide | 10.0 mg/1 | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Oral | Nov. 1, 2019 | In Use | |
67296-1738-08 | 67296-1738 | Metoclopramide | Metoclopramide | 10.0 mg/1 | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Oral | Nov. 1, 2019 | In Use | |
68071-1547-01 | 68071-1547 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 26, 2017 | Dec. 31, 2019 | In Use |
68071-1658-01 | 68071-1658 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 14, 2017 | Dec. 31, 2019 | In Use |
68071-1904-01 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 22, 2017 | In Use | |
68071-1904-02 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 22, 2017 | In Use | |
68071-1904-03 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 22, 2017 | In Use | |
68071-1904-04 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 22, 2017 | In Use | |
68071-1904-06 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 22, 2017 | In Use | |
68071-1968-01 | 68071-1968 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | Dec. 31, 2019 | No Longer Used |
68071-1968-02 | 68071-1968 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | Dec. 31, 2019 | No Longer Used |
68071-1968-03 | 68071-1968 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | Dec. 31, 2019 | No Longer Used |
68071-1968-04 | 68071-1968 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | Dec. 31, 2019 | No Longer Used |
68071-1968-06 | 68071-1968 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | Dec. 31, 2019 | No Longer Used |
68071-1987-01 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | In Use | |
68071-1987-02 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | In Use | |
68071-1987-03 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | In Use | |
68071-1987-04 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | In Use | |
68071-1987-06 | 68071-1987 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 23, 2017 | In Use | |
68071-2147-01 | 68071-2147 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 25, 2017 | In Use | |
68071-3028-02 | 68071-3028 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 14, 2017 | In Use | |
68071-3028-04 | 68071-3028 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 14, 2017 | In Use |
Found 10,000 results in 4 milliseconds — Export these results